Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026 

Rhea-AI Summary

Immunovant (Nasdaq: IMVT) will report financial results for the fourth quarter and fiscal year ended March 31, 2026 and provide a business update on Wednesday, May 20, 2026 at 8:00 a.m. ET. Access details and the archived webcast will be available on Immunovant’s investor website.

News Market Reaction – IMVT

-1.41%

2 alerts

-1.41% Session close to close

-10.1% Trough Tracked

$6.14B Market Cap

0.0x Rel. Volume

In the May 12 session, IMVT declined 1.41%, reflecting a mild negative market reaction. Argus tracked a trough of -10.1% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets the timetable for Immunovant’s fourth-quarter and full-year results for the p...

Analysis

This announcement sets the timetable for Immunovant’s fourth-quarter and full-year results for the period ending March 31, 2026, along with a business update on May 20, 2026 at 8:00 a.m. ET. It follows recent clinical data, large-scale financing, and prior scheduled earnings notices. Investors may focus on how upcoming results contextualize the Phase 3 TED outcome, prior capital raise, and ongoing IMVT-1402 programs, while comparing the communication cadence to earlier quarters.

Key Figures

Earnings call time: 8:00 a.m. ET Fiscal year-end: March 31, 2026 Earnings call date: May 20, 2026

3 metrics

Earnings call time 8:00 a.m. ET Scheduled earnings and business update on May 20, 2026

Fiscal year-end March 31, 2026 Fiscal year for upcoming reported results

Earnings call date May 20, 2026 Date of scheduled financial results and business update

Previous Earnings date Reports

1 past event · Latest: Jan 23 (Neutral)

Same Type Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
Jan 23	Earnings date notice	Neutral	+2.3%	Announcement of Q3 FY2025 earnings date and related business update call.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Prior earnings-date scheduling news saw a modest positive move in the shares.

Recent Company History

Over the last several months, Immunovant has combined clinical, financing, and scheduled-update news. A key recent event was the April 2, 2026 Phase 3 TED result for batoclimab, which missed its primary endpoint and saw a modest negative reaction. Earlier, the company strengthened its balance sheet with a $550 million equity financing in December 2025, followed by Q3 fiscal results and updates in February 2026. The current announcement continues the pattern of pre-announced dates for quarterly results and business updates.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DURHAM, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the fourth quarter and fiscal year ended March 31, 2026, and provide a business update at 8:00 a.m. ET on Wednesday, May 20, 2026.

To access the Roivant (Nasdaq: ROIV) conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under “News & Events” in the Investors section of the Immunovant website at https://www.immunovant.com/investors/news-events/ir-calendar. The archived webcast will be available on Immunovant’s website after the conference call.

About Immunovant 

Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com. 

Contacts: 

Investors 

Keyur Parekh 

keyur.parekh@roivant.com  

Media 

Stephanie Lee 

stephanie.lee@roivant.com 

FAQ

When will Immunovant (IMVT) report Q4 and fiscal year 2026 results?

Immunovant will report its Q4 and fiscal year ended March 31, 2026, results on May 20, 2026, at 8:00 a.m. ET. According to Immunovant, the update will include a business overview alongside the financial results via webcast and conference call.

How can investors access the Immunovant (IMVT) Q4 2026 earnings conference call?

Investors can access the Immunovant Q4 2026 conference call by registering online via the Roivant-hosted phone registration link. According to Immunovant, presentation and webcast details will be posted under “News & Events” in the Investors section of its website before the call.

Will a replay of the Immunovant (IMVT) May 20, 2026 earnings call be available?

Yes, a replay of the May 20, 2026 Immunovant earnings call will be available. According to Immunovant, an archived webcast of the presentation and business update will be accessible on the company’s investor relations website after the conference call concludes.

Where on Immunovant’s website can I find details for the May 20, 2026 (IMVT) webcast?

Details for the May 20, 2026 Immunovant webcast will be listed under “News & Events” in the Investors section. According to Immunovant, the IR calendar page will provide links to the live webcast and related presentation information for shareholders.

What will Immunovant (IMVT) cover during the May 20, 2026 business update?

Immunovant will cover financial results for its fourth quarter and fiscal year ended March 31, 2026, plus a business update. According to Immunovant, this includes prepared remarks on results and corporate developments, followed by access via webcast and conference call.